Activity Summary:
Despite advancements in diagnostics and therapeutics, Hypertrophic Cardiomyopathy (HCM) remains underdiagnosed and inconsistently managed across clinical settings. Clinicians often struggle to identify early signs of HCM, differentiate it from similar cardiac conditions, and apply evolving risk stratification tools and treatment strategies. Traditional therapies provide limited symptom relief and do not address the underlying pathophysiology, while the integration of newer disease-modifying agents such as Cardiac Myosin Inhibitors (CMIs) is still evolving in practice.

During this video series, Drs. Theodore Abraham and Martin Maron address these challenges aiming to improve the recognition, diagnosis, and management of HCM.

Activity Summary:
Pulmonary hypertension (PH) remains a serious and often underrecognized complication in patients with interstitial lung disease (ILD), significantly contributing to increased morbidity, mortality, and overall healthcare burden. Because of the clinical overlap between fibrotic lung disease and PH, early signs are frequently missed, leading to delays in diagnosis and limited opportunities for timely intervention. Evolving definitions and diagnostic criteria for PH further highlight the need to refine and update current screening approaches—especially for patients with early or borderline disease.

In this expert-led podcast, Dr. Nathan shares practical insights on recognizing early indicators of PH in the setting of ILD, interpreting key diagnostic findings, and applying effective risk stratification strategies. The discussion focuses on improving early detection and optimizing management to ultimately enhance outcomes for this high-risk patient population.

Activity Summary:
To further build on the insights presented in the Clinical Clips® in NF1-PN: Key Advances from AAN 2026 by Dr. Angela Hirbe, HCPs can access a range of downloadable resources designed to reinforce key concepts and support practical application in clinical care.

Available Resources:

Clinical Snippet Highlights: AAN 2026 Evidence at a Glance
A PDF summarizing each key presentation or poster featured in the Clinical Clip, with evidence-based takeaways for each study.

Downloadable Slide Deck (PDF)
Downloadable version of the presentation slides used by the faculty, including data visuals, figures, and key discussion points.

Expert Commentary Transcript
A transcript of the podcast version of the program, reflecting the expert discussion and interpretation of AAN 2026 data.

Discussion Guide: Applying Emerging NF1 Evidence Across the Lifespan
A brief guide with reflective questions and prompts related to patient selection, interpretation of outcomes beyond imaging, and longitudinal management considerations.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:
RRMM remains a challenging and rapidly evolving disease state, especially at first relapse, where decisions around risk stratification, treatment selection, and sequencing can shape long-term outcomes. With expanding therapeutic options, including immunotherapies, and continually evolving clinical guidance, staying current is increasingly complex.

Join Drs. Ajai Chari and Sagar Lonial for a dynamic 60-minute live webcast designed to help you navigate these decisions with confidence. Through expert insights, interactive case-based discussions, and clinically relevant strategies you can apply in real-world settings, this program goes beyond the basics. Real-time polling and decision-based learning will reinforce key concepts and support more confident, evidence-informed care.

Reserve your spot today and stay ahead in the evolving management of RRMM.

Activity Summary:
To further expand knowledge from the Advancing Myasthenia Gravis Care: Emerging Insights from AAN 2026 presented by Dr. James Howard Jr., HCPs can access a variety of downloadable resources designed to reinforce and enhance information that can be utilized directly in clinical settings or for further study and reference.

Available Resources:

Clinical Snippet Highlights: AAN 2026 Evidence in Myasthenia Gravis
A summary highlighting each abstract, presentation, or poster discussed in the Clip, with key findings, clinical relevance, and practical takeaways.

Downloadable Slides
Downloadable PDF of presentation slides, including data visuals, algorithms, and expert insights - ideal for review, teaching, or clinical discussions.

Podcast Transcript
A downloadable transcript of the podcast/video for learners who prefer text-based review or need an offline resource.

Diagnostic and Severity Assessment Quick Reference
A reference guide summarizing diagnostic considerations, testing options, and commonly used severity assessment tools discussed in the program.

Emerging Treatment Landscape Overview
An overview outlining emerging treatment strategies covered in the Clip, including mechanisms of action and potential clinical considerations.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:
Leveraging emerging evidence presented at AAN, Dr. Angela Hirbe provides a synthesis of key findings, highlight their relevance across pediatric and adult care, and frames practical considerations for patient assessment and longitudinal management.

Activity Summary:
Clinical care for myasthenia gravis is entering a period of meaningful progress, with growing opportunities to improve how the disease is diagnosed, assessed, and treated. Increased awareness of disease heterogeneity and the expanding use of standardized severity assessments are helping clinicians better define disease burden and guide management decisions.

In this 20-minute podcast episode, Dr. James Howard Jr. provides comprehensive coverage of key MG presentations, scientific symposia, posters, and abstracts presented at AAN 2026.

Activity Summary:
PH is a serious and frequently underdiagnosed complication in patients with ILD, contributing to increased morbidity, mortality, and healthcare burden. The clinical overlap between fibrotic lung disease and PH often results in delayed recognition and missed opportunities for early intervention. Recent updates to PH definitions and diagnostic criteria underscore the importance of revising clinical screening strategies, particularly for patients with borderline or early-stage disease.

During this expert led video, Dr. Nathan presents key insights on identifying early signs of PH in ILD, interpreting relevant diagnostic data, and appropriately stratifying risk – aiming to improve diagnosis, management, and outcomes in this high-risk population.

Activity Summary:
Neurofibromatosis type 1 (NF1) treatment is evolving rapidly, with new data emerging across clinical trials and real-world studies. For busy clinicians, the challenge is not access to information, but quickly understanding what is clinically meaningful and how it should influence care.

This Clinical Clip from AAN 2026 delivers a focused, expert-led review of emerging NF1-PN treatment data in just 10-minutes. Designed for real-world practice, this concise update highlights key findings, clarifies their clinical relevance, and provides practical insights to support patient selection and treatment decisions.

Watch the clip to stay current, sharpen your clinical thinking, and translate new evidence into action.

Activity Summary:
Myasthenia gravis care is advancing quickly, with new evidence shaping how clinicians approach disease assessment and treatment selection. At the same time, variability in presentation, delays in diagnosis, and uncertainty around integrating emerging therapies continue to create challenges in clinical practice. Clinicians need concise, practical education that translates evolving data into clear and actionable strategies that can be applied in real-world care.

This focused Clinical Clip from AAN 2026 features Dr James (Chip) Howard, a leading expert in myasthenia gravis, delivering a 20-minute update on the most clinically relevant advances presented in Chicago. Designed for efficiency and practical application, this program highlights how to incorporate emerging therapies into individualized treatment plans to support confident, evidence-based decision-making.

Activity Summary:
Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.

These educational podcasts will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with a series of "what you need to know" podcast episodes from data presented at CROI 2026.

Activity Summary:
Advances in HIV research often unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.

These educational Clinical Clips will spotlight the latest advances in the treatment and prevention of HIV and related comorbidities with a series of "what you need to know" videos from data presented at CROI 2026.

Activity Summary:
To reinforce key insights and facilitate post-activity implementation, participants can download, on-demand resources designed to support ongoing clinical decision-making. These concise, easy-to-reference tools translate emerging evidence into practical strategies that clinicians can reference when integrating today’s most effective therapeutic approaches.

Clinical Slide Deck:
A curated set of high-yield, evidence-based slides including data visuals, algorithms, and expert insights.

Expert Commentary Transcripts:
A downloadable transcript of the podcast/video for learners who prefer a text-based review.

Strengthen your knowledge. Support your practice. Improve patient care.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:

CAR T-cell therapies have transformed the management of several previously incurable, treatment-refractory hematologic malignancies, including Multiple Myeloma (MM). With two CAR T-cell products now approved, and additional under investigation, the therapeutic landscape continues to evolve rapidly.

In this educational podcast, Dr. Joseph Mikhael highlights key advances in CAR T-cell therapy for MM. He reviews the most impactful data published or presented in 2025 and offers expert insight into how these emerging findings may shape current and future treatment strategies.

Activity Summary:

CAR T-cell therapies have revolutionized the treatment of several, previously incurable, refractory hematologic malignancies, including Multiple Myeloma (MM). While two CAR T-cell products are now approved and several are under investigation for MM.

During this educational presentation, Dr. Joseph Mikhael reviews important breakthroughs of CAR T-cell therapy in MM. Throughout the video he highlights the most relevant updates in CAR T-cell therapy from 2025 key studies and publications, as well as provides insights into the implications of these developments on the treatment landscape.

Activity Summary:
To further expand knowledge from the What's New Doc? End-of-the-Year Updates on IPF presented by Dr. Steven Nathan, HCPs can access a variety of downloadable resources designed to reinforce and enhance information that can be utilized directly in clinical settings or for further study and reference.

Available Resources:

Clinical Snippet Highlights
Concise, one-page summaries of key IPF studies featured in this activity, offering quick, actionable insights to support day-to-day clinical decision-making.

Downloadable Slides
Downloadable PDF of presentation slides, including data visuals, algorithms, and expert insights - ideal for review, teaching, or clinical discussions.

Expert Commentary Transcript
A downloadable transcript of the podcast/video for learners who prefer text-based review or need an offline resource.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:
These clinical videos and podcasts are accredited, on-demand presentations that feature experts discussing recent clinical updates, hot topics and treatment options that were presented at the annual hematology meeting December 6-9 in Orlando, FL. These activities are designed to keep healthcare professionals abreast of the most recent clinical findings.

This series of conference highlights covers leukemia, myelodysplastic syndromes (MDS), myelofibrosis (MF), as well as hemophilia A and B. Please click the links to participate in each of these activities.

Activity Summary:
A number of clinical trials are underway to reduce and prevent bleeding episodes among patients with hemophilia and to improve their overall quality of life by improving joint health and addressing patient needs/concerns. These include both replacement and novel non-replacement therapies. This activity is designed to update healthcare professionals with the latest cutting-edge evidence in hemophilia treatment that was presented during the annual hematology meeting in Orlando, FL.

The Clinical Clips format will equip clinicians with the knowledge and confidence to integrate new evidence into personalized approaches, optimize patient outcomes, and improve the overall quality of care in hemophilia A and B.

Activity Summary:
Enhance your learning from the Hematologic Cancer Updates activity with a curated resource library built for real-world clinical needs. Access downloadable visual summaries, practical takeaways and ready-to-share content—ideal for quick reference and team-based discussions, and perfectly aligned with the podcast and highlights video.

Clinical Slide Deck: Downloadable PDF of presentation slides, including data visuals, algorithms and expert insights—ideal for review, teaching or clinical discussions.

Clinical Snippet Highlights: Concise, one-page summaries of key posters and abstracts, offering quick, actionable insights to support day-to-day clinical decision-making.

Expert Commentary Transcript: A downloadable transcript of the podcast/video for learners who prefer text-based review or need an offline resource.

This activity is not designated for continuing education credit. This is in no way a reflection of the integrity or quality of the content.

Activity Summary:
Despite advances in understanding PAH, several opportunities remain to further improve patient outcomes, particularly in timely diagnosis, the differentiation to other PH subtypes, treatment challenges, and the management of cardiovascular comorbidities.

During these two Clinical Snippet episodes, Dr. Oudiz highlights the latest advances in PAH that were presented at fall conferences in Seattle, WA; Chicago, IL; and Amsterdam, Netherlands in September-October 2025.

Activity Summary:

A number of clinical trials are underway to reduce and prevent bleeding episodes among patients with hemophilia and to improve their overall quality of life by improving joint health and addressing patient needs/concerns. These include both replacement and novel non-replacement therapies. This activity is designed to update healthcare professionals with the latest cutting-edge evidence in hemophilia treatment that was presented during the annual hematology meeting in Orlando, FL.

The Clinical Clips format will equip clinicians with the knowledge and confidence to integrate new evidence into personalized approaches, optimize patient outcomes, and improve the overall quality of care in hemophilia A and B.

Activity Summary:
Breakthroughs in hematologic cancers continue to emerge. Staying aligned with the newest insights from leading medical conferences is essential for healthcare providers committed to delivering cutting-edge care.

Through impactful presentations, posters and abstracts, Dr. Raajit Rampal provides expert commentary on the latest advances in Leukemia, Myelodysplastic Syndromes (MDS), and Myelofibrosis (MF) presented at the annual hematology meeting in Orlando, FL.

Activity Summary:
PH is currently divided into groups based on the perceived etiology of the vascular insult: PAH (Group 1), PH due to left heart disease (Group 2), PH due to lung disease and/or hypoxia (Group 3), PH due to pulmonary artery obstructions (Group 4), and PH due to unclear and/or multifactorial mechanisms (Group 5). Accordingly, therapeutic interventions to address PH differ significantly between groups. However, this classification is less than perfect as there is not only considerable heterogeneity within each group but also overlap between groups. Emerging evidence on phenotyping PH may assist to address these limitations. This educational slide kit presents the latest research in diagnosing and managing Group 2-5 in patients, including the distinction of specific groups – CTEPH, PH-ILD, PH-COPD, CPFE, CTD.

Activity Summary:
Novel therapies and combinations are currently under investigation for the treatment of acute myeloid leukemia (AML). These include venetoclax, FLT3 inhibitors, IDH inhibitors, menin inhibitors, antibody-drug conjugates, CAR T-cell approaches, and novel targeted agents. Similarly, a number of clinical trials are underway for other leukemias, myelodysplastic syndromes (MDS), and myelofibrosis (MF).

In this Conference Highlights accredited video, Dr. Raajit Rampal discusses the latest cutting-edge evidence in leukemia, MDS and MF, presented in Orlando, FL December 6th – 9th, integrating new evidence into personalized approaches, optimizing patient outcomes, and improving the overall quality of care.